Quick Answer
Dyne Therapeutics, Inc. reported Total Assets of $1.19 billion for the year ending 2025.
- Dyne Therapeutics, Inc. showed an increase of +71.7% in Total Assets from 2024 to 2025.
- This data is from Dyne Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $381.47 million | Q1 2021: $491.71 million | Q2 2021: $467.15 million | Q3 2021: $466.88 million | Q1 2022: $387.76 million | Q2 2022: $340.03 million | Q3 2022: $299.68 million | Q1 2023: $288.64 million | Q2 2023: $251.42 million | Q3 2023: $205.24 million | Q1 2024: $522.28 million | Q2 2024: $825.88 million | Q3 2024: $768.84 million | Q1 2025: $721.07 million | Q2 2025: $728.99 million | Q3 2025: $867.06 million.
- Over the full 7 years of available data (2019 to 2025), Dyne Therapeutics, Inc.'s Total Assets has grown by 7,121.7%.
- Historical annual values: Fiscal year 2025: $1.19 billion | Fiscal year 2024: $691.23 million | Fiscal year 2023: $165.08 million | Fiscal year 2022: $306.33 million | Fiscal year 2021: $425.66 million | Fiscal year 2020: $353.33 million | Fiscal year 2019: $16.44 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: